Nektar Therapeutics (NKTR) Invested Capital (2010 - 2020)

Nektar Therapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $254.1 million for Q1 2020.

• In Q1 2020, Invested Capital changed N/A year-over-year to $254.1 million; the TTM figure through Dec 2020 stood at $254.1 million (changed 0.5% YoY), while the FY2019 annual figure was $252.9 million, changed N/A from the prior year.
• Invested Capital for Q1 2020 stood at $254.1 million, roughly flat from $252.9 million in the prior quarter.
• The five-year high for Invested Capital was $254.1 million in Q1 2020, with the low at $3.0 million in Q3 2017.
• The 4-year median for Invested Capital is $5.1 million (2016), against an average of $60.3 million.
• The sharpest annual moves came in 2016 and 2017: Invested Capital slipped 12.07% in 2016, then tumbled 44.44% in 2017.
• Nektar Therapeutics' Invested Capital stood at $5.1 million in 2016, then sank by 41.18% to $3.0 million in 2017, then surged by 8329.7% to $252.9 million in 2019, then advanced by 0.5% to $254.1 million in 2020.
• Business Quant data shows NKTR's Invested Capital at $254.1 million in Q1 2020, $252.9 million in Q4 2019, and $3.0 million in Q3 2017.